Everist Genomics has launched four companion diagnostics intended to improve early diagnosis, management, and treatment of patients with colorectal cancer.

The tests, which will be available in the US at the end of March, include:

OncoDefender-MMR, used for prognosis for colorectal cancer patients at all stages of the disease;

OncoDefender-CRC, designed to identify early-stage colorectal cancer patients likely to benefit from adjuvant chemotherapy;

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.